Page 908 - Veterinary Immunology, 10th Edition
P. 908

VetBooks.ir  Some Antiviral Vaccines





               Because of the lack of antiviral drugs, vaccination is the only
               effective method for the control of most viral diseases in domestic

               animals. As a result, the development of viral vaccines is, in many
               ways, more advanced than the development of their bacterial
               counterparts. It has, for example, proved relatively easy to
               attenuate many viruses so that effective vaccines containing
               modified live virus (MLV) are readily available.

                  As discussed in Chapter 25, MLV vaccines are usually good
               immunogens, but their use may involve certain risks. The most
               important problem encountered is residual virulence. One serious

               example of this was the development of clinical rabies in some dogs
               and cats following administration of older strains of MLV rabies
               vaccine. Some strains of infectious bovine rhinotracheitis and
               equine herpesvirus-1 vaccines may cause abortion when given to
               pregnant cows or mares, respectively, and MLV bluetongue

               vaccines may cause disease in fetal lambs if given to pregnant ewes
               (Chapter 23). More commonly, the residual virulence in these
               vaccines causes a mild disease. Thus intraocular or intranasal

               rhinotracheitis or calicivirus vaccines may cause a transient
               conjunctivitis or rhinitis in cats. MLV infectious bursal disease
               vaccines, some canine parvovirus-2 vaccines, and some bovine viral
               diarrhea vaccines can cause a mild immunosuppression (see Fig.
               40.1).

                  Because of problems of this nature, attempts have been made to
               minimize residual virulence in vaccines. One method involves the
               use of temperature-sensitive (ts) mutants. Ts strains of BHV-1, for

               example, will grow only at temperatures a few degrees lower than
               normal body temperature. When this organism is administered
               intranasally, it is able to colonize the relatively cool nasal mucosa
               but is unable to invade the rest of the body. Thus the vaccine can
               stimulate local immunity without incurring the risk for a systemic

               invasion. (It also has the advantage that its activity is not blocked
               by maternal immunity.) Some vaccine viruses may persist in
               vaccinated animals and cause a prolonged carrier state. Although

               this is a problem largely associated with herpesviruses, concerns




                                                         908
   903   904   905   906   907   908   909   910   911   912   913